about
Interventional tools to improve medication adherence: review of literatureTen years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.[Platelet indices in chronic alcoholic liver disease patients with thrombocytopenia].Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese.Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis.Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene Expression.Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration.Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model.Bilirubin is independently associated with oxidized LDL levels in young obese patients.Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification.Interventional Tools to Improve Prescription and Adherence to Medical Plans.Hematologically important mutations: bilirubin UDP-glucuronosyltransferase gene mutations in Gilbert and Crigler-Najjar syndromes.Predictors of Difficulty in Medication Intake in Europe: a Cross-country Analysis Based on SHARE.Risk factors for mortality in hemodialysis patients: two-year follow-up study.Frailty in End-Stage Renal Disease Patients under Dialysis and Its Association with Clinical and Biochemical Markers.Hydroxyapatite-based materials of marine origin: a bioactivity and sintering study.Physical inactivity among older adults across Europe based on the SHARE database.Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board.Chronic case management: Clinical governance with cost reductions.Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat.Adipokine Gene Single-Nucleotide Polymorphisms in Portuguese Obese Adolescents: Associations with Plasma Concentrations of Adiponectin, Resistin, IL-6, IL-1β, and TNF-α.Biochemical and cellular changes in leukocyte-depleted red blood cells stored for transfusionPathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia.Risk factors for mortality in end-stage kidney disease patients under online-hemodiafiltration: three-year follow-up study.Liver iron is a major regulator of hepcidin gene expression via BMP/SMAD pathway in a rat model of chronic renal failure under treatment with high rHuEPO doses.SELF-REPORTED MEDICATION ADHERENCE IN PATIENTS WITH END-STAGE KIDNEY DISEASE UNDERGOING ONLINE-HAEMODIAFILTRATION.Economic analysis of costs with enteral and parenteral nutritional therapy according to disease and outcome.Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project).A new case of (TA)8 allele in the UGT1A1 gene promoter in a Caucasian girl with Gilbert syndrome.Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat.Modulation of human dermal microvascular endothelial cell and human gingival fibroblast behavior by micropatterned silica coating surfaces for zirconia dental implant applications.Cardiovascular risk factors in portuguese obese children and adolescents: impact of small reductions in body mass index imposed by lifestyle modifications.Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia.Polymorphisms of the ELANE Gene Promoter Region in End-Stage Chronic Kidney Disease Patients.Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment.Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.Erythrocyte membrane protein destabilization versus clinical outcome in 160 Portuguese Hereditary Spherocytosis patients.Aging and cardiovascular risk.Erythropoiesis versus inflammation in Hereditary Spherocytosis clinical outcome.Characterization of a rat model of moderate chronic renal failure--focus on hematological, biochemical, and cardio-renal profiles.
P50
Q26781959-1EB9B45C-BF79-46B6-82E2-2606CF7FFFEFQ33337516-00E5DEBF-77B5-4FFD-AC27-A6E060C9C91DQ33377672-E62F9FF1-378A-4A46-9050-4B280FBC5EFAQ33716871-1642622A-EBE9-416E-BE9D-AAAD6EC702F4Q34243084-7F7BA515-DB4E-4F16-93F4-0584F62AD467Q34599292-D98CB9D5-2746-4DA2-B32D-41507D1BEE45Q35013331-FE471979-F83F-4A82-8424-FA4398F3848FQ35388676-2EAE7951-9165-4464-8C58-AA071A82BBE5Q35599188-CA055696-EADB-45C9-AB6D-2451289902D9Q36064517-A38EEA1B-BA84-47A6-A7C1-2645354FBFA1Q36353023-07F4A4B2-05CA-47AA-B399-6E3B6C7355C1Q36357365-0A504033-BA2B-412D-B2C2-1E2633EBAF82Q36983492-234988CF-6B62-4960-B308-D0BB9BFD03E2Q37379663-796C29C1-2C16-40D5-9B60-3AE649029E61Q38757652-48D3DB83-5F2A-4B08-87A4-9890D1D685C4Q38890968-00CFE110-1E97-413C-8593-CCB9995B7D74Q38970241-802DD75A-3796-4C46-BC49-33BA31788787Q39574426-B1394396-17D4-48D6-A167-A27E5D48ED1BQ39678441-D24F9624-DFED-42BD-AA9C-66D4963F0BFCQ39695735-D104F30A-291C-475D-958E-F2B0DD67D6EEQ39783035-DDFEB760-45A3-4074-A999-3D6C6E91C1FAQ39835742-34A36AF9-A482-4EEE-AAC7-98ED8E50A06FQ39868793-BA722F16-B86E-475A-991C-201B6F95B04EQ39877729-001D3143-D920-4A58-8C8C-8626A1A9562CQ39909865-AEF8D371-D064-4AE8-85D4-E904CF04016DQ40106865-E671D9D0-F72B-4AFD-AA3D-3B9FE4616C06Q40109848-96EC31AD-5DC0-47F5-B8EB-947D6FFC6F3EQ40165178-AC62D3B8-5378-4103-A99F-20D4B006302CQ40531638-F05EEF6B-D0B5-4591-AB01-818D6AE61568Q41398632-264FA379-07C2-43C7-9D08-36454C4FE557Q41645329-54713E0F-58E9-4BE0-A2DD-81906F0DD6F1Q42176611-C5BE27E2-6910-43F8-82D8-F991ED744873Q42180857-C940DDB5-9F99-46D7-A0F5-944869883240Q42760947-C0A00436-BBA9-49F1-9990-356293B01524Q42849568-2F854955-8703-45CF-8406-72B4A4BF0897Q43064681-501FD5EE-679A-4E17-9B0D-0304039D5CD5Q43117298-1E7F1D40-2F9E-4E42-B4CE-0FF55FA45B62Q43191134-6CAE5065-1B22-4D69-937A-3BEB0CAA0836Q43447272-E1A678DA-D206-4392-9E56-5F82E3BC057FQ43664074-A921EFC1-2BF5-44EE-A300-54194C9E14A1
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Elísio Costa
@ast
Elísio Costa
@en
Elísio Costa
@es
Elísio Costa
@nl
Elísio Costa
@sl
type
label
Elísio Costa
@ast
Elísio Costa
@en
Elísio Costa
@es
Elísio Costa
@nl
Elísio Costa
@sl
prefLabel
Elísio Costa
@ast
Elísio Costa
@en
Elísio Costa
@es
Elísio Costa
@nl
Elísio Costa
@sl
P108
P214
P1005
P1053
K-1990-2013
P106
P108
P1153
7402527214
P21
P213
0000 0000 6990 0198
P214
P31
P3829
P496
0000-0003-1158-1480
P734
P7859
viaf-98954525